Brewin Dolphin LTD Editas Medicine, Inc. Transaction History

Brewin Dolphin LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 14, 2022	SELL	$9.99 - $21.35 $9,190 - $19,642	-920 Closed	0 $0
Q1 2022 Nov 14, 2022	BUY	$14.08 - $27.63 $12,953 - $25,419	920 New	920 $17,000
Q2 2021 Nov 09, 2023	BUY	$31.29 - $56.64 $28,786 - $52,108	920 Added 550.9%	1,087 $61.6 Million
Q1 2021 Nov 09, 2023	SELL	$39.71 - $90.58 $1,985 - $4,529	-50 Reduced 23.04%	167 $7.01 Million
Q4 2020 Nov 09, 2023	BUY	$27.07 - $84.35 $1,353 - $4,217	50 Added 29.94%	217 $15.2 Million
Q1 2019 Nov 09, 2023	BUY	$19.43 - $26.41 $3,244 - $4,410	167 New	167 $4.08 Million
Q3 2018 Nov 09, 2023	SELL	$27.65 - $38.39 $23,917 - $33,207	-865 Closed	0 $0
Q2 2018 Nov 09, 2023	SELL	$31.4 - $41.01 $3,705 - $4,839	-118 Reduced 12.0%	865 $31 Million
Q3 2017 Nov 09, 2023	BUY	$15.81 - $24.01 $15,541 - $23,601	983	983 $23.6 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.2M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Brewin Dolphin LTD, based on Form 13F filings with the SEC.

Stay updated on Brewin Dolphin LTD with notifications on news.